- Home
- FLGC vs BIVI Comparison
FLGC vs BIVI Comparison
Compare FLGC & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLGC
- BIVI
- Stock Information
- Founded
- FLGC 2019
- BIVI 2013
- Country
- FLGC United States
- BIVI United States
- Employees
- FLGC N/A
- BIVI N/A
- Industry
- FLGC Biotechnology: Pharmaceutical Preparations
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- FLGC Health Care
- BIVI Health Care
- Exchange
- FLGC Nasdaq
- BIVI Nasdaq
- Market Cap
- FLGC 13.5M
- BIVI 14.2M
- IPO Year
- FLGC 2021
- BIVI N/A
- Fundamental
- Price
- FLGC $7.87
- BIVI $1.44
- Analyst Decision
- FLGC Strong Buy
- BIVI
- Analyst Count
- FLGC 1
- BIVI 0
- Target Price
- FLGC $156.00
- BIVI N/A
- AVG Volume (30 Days)
- FLGC 20.4K
- BIVI 97.4K
- Earning Date
- FLGC 11-05-2025
- BIVI 11-10-2025
- Dividend Yield
- FLGC N/A
- BIVI N/A
- EPS Growth
- FLGC N/A
- BIVI N/A
- EPS
- FLGC N/A
- BIVI N/A
- Revenue
- FLGC $57,609,000.00
- BIVI N/A
- Revenue This Year
- FLGC N/A
- BIVI N/A
- Revenue Next Year
- FLGC $10.48
- BIVI N/A
- P/E Ratio
- FLGC N/A
- BIVI N/A
- Revenue Growth
- FLGC 24.71
- BIVI N/A
- 52 Week Low
- FLGC $7.12
- BIVI $1.37
- 52 Week High
- FLGC $81.90
- BIVI $38.50
- Technical
- Relative Strength Index (RSI)
- FLGC 27.45
- BIVI 32.18
- Support Level
- FLGC $7.12
- BIVI $1.37
- Resistance Level
- FLGC $7.98
- BIVI $1.56
- Average True Range (ATR)
- FLGC 0.96
- BIVI 0.11
- MACD
- FLGC 0.13
- BIVI -0.01
- Stochastic Oscillator
- FLGC 10.59
- BIVI 8.27
About FLGC Flora Growth Corp.
Flora Growth Corp is a multi-national cannabis company that manufactures and distributes consumer packaged goods, cultivates and distributes medicinal cannabis, and distributes pharmaceutical products. Its reportable segments are: the commercial and wholesale segment (FGH and Cosechemos subsidiaries) and the house of brands segment (JustCBD, Vessel, and Kasa Wholefoods Company subsidiaries). Geographically, the company generates revenue from the United States, Germany, Australia, and the United Kingdom. It generates revenue as a distributor of pharmaceutical goods, and a manufacturer and reseller of a range of cannabis-based and complementary products.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.